Avadel (Nasdaq: AVDL) is a biopharmaceutical company focused on transforming medicines to transform lives. Our approach includes applying innovative solutions to the development of medications that address the challenges patients face with current treatment options. Our current lead drug candidate, FT218, is an investigational formulation of sodium oxybate leveraging our proprietary drug delivery technology and designed to be taken once at bedtime for the treatment of excessive daytime sleepiness and cataplexy in adults with narcolepsy.
At Avadel, our core values foster an atmosphere of innovation and collaboration. In everything we do, we consider the patient experience, listening to their needs as we pursue the development and delivery of medicines that will transform the treatment landscape and have the greatest impact on people living with narcolepsy.
Learn more about us at www.avadel.com and follow us on Twitter at @AvadelPharma.
Location: Ireland, Leinster, Dublin
Employees: 51-200
Founded date: 1990
Investors 1
| Date | Name | Website |
| - | Avoro Capi... | avorocapit... |
Mentions in press and media 2
| Date | Title | Description | Source |
| 05.03.2024 | Avadel Pharmaceuticals to Present at Upcoming Investor Confe... | - | globenewsw... |
| 30.03.2023 | Avadel Pharmaceuticals to Provide a Corporate Update and Rep... | DUBLIN, Ireland, March 29, 2023 (GLOBE NEWSWIRE) -- Avadel Pharmaceuticals plc AVDL, a biopharmaceut... | einpresswi... |